ProCE Banner Activity

Updates on BTKi Therapy for COVID-19 and Considerations for Patients With CLL

Clinical Thought
What are the latest data on BTK inhibitors to treat COVID-19? How are you managing your patients with CLL going forward? Here, I share my experiences and thoughts on the implications of the latest data and emerging vaccine approvals for patients with CLL.

Released: December 16, 2020

Expiration: December 15, 2021

Share

Faculty

Jacqueline Barrientos

Jacqueline Barrientos, MD, MS

Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Attending Physician
Division of Hematology/Oncology
Northwell Health System
Lake Success, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Jacqueline Barrientos, MD, MS

Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Attending Physician
Division of Hematology/Oncology
Northwell Health System
Lake Success, New York

Jacqueline Barrientos, MD, MS, has disclosed that she has received funds for research support from Oncternal; consulting fees from AstraZeneca, Bayer, Genentech, Gilead Sciences, and Sandoz; and other financial or material support from Janssen.